论文部分内容阅读
目的为了探讨来氟米特和硫唑嘌呤联合波尼松与霉酚酸酯联合波尼松治疗狼疮肾炎的临床疗效及安全性。方法按照随机双盲对照的原则将2011年10月~2013年9月期间来本院就诊的20例狼疮肾炎患者分为观察组和对照组,观察组患者采取来氟米特、硫唑嘌呤联合波尼松进行治疗,对照组患者采取霉酚酸酯联合波尼松进行治疗,在治疗后观察两组患者疗效情况。结果经过治疗数据显示,在经不同的药物进行治疗后对照组与观察组患者疗效有差异,观察组显效患者8例(80.00%)较对照组显效患者4例(40.00%)多,总有效率对照组8例(80.00%),观察组10例(100.00%)。结论狼疮肾炎患者采取来氟米特、硫唑嘌呤联合波尼松进行治疗较霉酚酸酯联合波尼松疗效显著,应在临床上广泛应用。
Objective To investigate the clinical efficacy and safety of leflunomide and azathioprine in combination with prednisolone and mycophenolate combined with prednisone in the treatment of lupus nephritis. Methods According to the principle of randomized double-blind control, 20 patients with lupus nephritis treated in our hospital from October 2011 to September 2013 were divided into observation group and control group. The patients in observation group were treated with leflunomide and azathioprine The patients in the control group were treated with mycophenolate mofetilon together with prednisone. The curative effect of the two groups was observed after treatment. Results After the treatment data showed that in the control group and observation group after treatment by different drugs there are differences in the efficacy of the observation group of 8 patients (80.00%) than the control group markedly effective in 4 patients (40.00%), the total effective rate 8 cases (80.00%) in the control group and 10 cases (100.00%) in the observation group. Conclusions The treatment of lupus nephritis with leflunomide and azathioprine combined with prednisone is more effective than mycophenolate in combination with prednisolone and should be widely used clinically.